Sales & Support: +86 15190047243
  • linkedIn
English
English French German Portuguese Spanish Russian Japanese Korean Arabic Turkish Italian Indonesian Polish Hindi Dutch Malay Persian Thai Vietnamese
Inquiry
Form loading...
Products Categories
Featured Products
Upadacitinib (Crystal Form C)
Upadacitinib (Crystal Form C)
Isoquinoline
Isoquinoline
Information
Information
Quinoline
Quinoline
Netupitant
Netupitant
N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-amine
N-methyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-amine
2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid
2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid
Lefamulin acetate
Lefamulin acetate
tert-butyl ((1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl)carbamate
tert-butyl ((1R,3R,4R)-3-hydroxy-4-mercaptocyclohexyl)carbamate
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate
(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(tosyloxy)acetate
0102030405
Sparsentan.jpg

Sparsentan Active Pharmaceutical Ingredient - Leading China Suppliers and Reliable Factory Production

Basic Information

Introducing our premium quality products sourced directly from trusted China suppliers and manufactured in our state-of-the-art factory. We specialize in delivering top-notch solutions tailored to meet your needs, ensuring exceptional performance and reliability. Our commitment to excellence guarantees that you receive only the best, while our competitive pricing reflects our dedication to providing value for your investment. Partner with us and experience the advantages of working with a leading supplier from China, where innovation meets quality in every product we create. Explore our range today and discover how our factory's capabilities can elevate your operations!
  • Generic Name Sparsentan
  • Chemical Name (Dual Endothelin-Vasopressin Receptor Antagonist) – A novel small-molecule therapeutic with combined endothelin receptor type A (ETA) and angiotensin II subtype 1 (AT1) antagonism.
  • Molecular Formula C34H34FN5O6S2
  • Molecular Weight 699.79 g/mol
  • Pharmacological Class Dual-acting endothelin-angiotensin receptor antagonist (DEARA)
  • Administration Route Oral (tablets/capsules)
Contact us
Product Details

Key Therapeutic Functions
◉ Primary Indication

Treatment of rare renal disorders, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), characterized by proteinuria and progressive loss of kidney function.

◉ Mechanism of Action

Dual Inhibition: Simultaneously blocks ETA receptors (reducing vasoconstriction, inflammation, and fibrosis) and AT1 receptors (lowering blood pressure and glomerular pressure).

Synergistic Effect: Combats pathogenic pathways in rare glomerular diseases by reducing proteinuria, preserving podocyte integrity, and delaying renal fibrosis.

◉ Clinical Efficacy

✔ Proven to significantly reduce proteinuria (up to 40–50% in clinical trials) compared to single-target therapies.

✔ Demonstrated renal protective effects, slowing the progression to end-stage renal disease (ESRD).

Technical Specifications
Dosage Forms Film-coated tablets (e.g., 200 mg, 400 mg strengths).
Pharmacokinetics High oral bioavailability with linear absorption.
Metabolized primarily via hepatic CYP450 enzymes (CYP3A4/5, CYP2C8).
Storage Store at controlled room temperature (20–25°C), protected from moisture and light.
Shelf Life 24 months under recommended storage conditions.
Therapeutic Applications
◉ Rare Kidney Diseases
FSGS

Targets podocyte injury and glomerular sclerosis in steroid-resistant patients.

IgA Nephropathy

Reduces mesangial proliferation and immune complex deposition.

Potential Expansion

Investigated for other proteinuric kidney diseases (e.g., diabetic nephropathy, membranous nephropathy).

Clinical & Safety Profile
Orphan Drug Designation (ODD) FDA Fast Track Status FSGS / IgAN Approved Indications
◉ Safety

Well-tolerated in trials; common adverse effects include peripheral edema, hypotension, and hyperkalemia (managed via dose adjustment).

◉ Monitoring

Regular renal function and electrolyte assessments recommended during therapy.

Why Sparsentan Stands Out?

Sparsentan represents a paradigm shift in rare nephrology by addressing dual pathogenic pathways with a single molecule. Its precision-engineered design ensures potent efficacy in reducing proteinuria and preserving renal function, offering hope for patients with limited treatment options. Backed by rigorous clinical evidence and robust manufacturing standards, Sparsentan is positioned as a breakthrough therapy for debilitating glomerular diseases.

Frequently Asked Questions
Q What is Sparsentan primarily used to treat?
Sparsentan is primarily indicated for the treatment of rare renal disorders, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both characterized by significant proteinuria and progressive kidney function decline.
Q How does Sparsentan's dual inhibition mechanism work?
Sparsentan simultaneously blocks ETA receptors — reducing vasoconstriction, inflammation, and fibrosis — and AT1 receptors, which lowers blood pressure and glomerular pressure. This dual blockade creates a synergistic effect that addresses multiple disease pathways with a single molecule.
Q What clinical evidence supports Sparsentan's efficacy?
Clinical trials have demonstrated that Sparsentan can reduce proteinuria by up to 40–50% compared to single-target therapies. It has also shown renal protective effects, significantly slowing the progression toward end-stage renal disease (ESRD).
Q Has Sparsentan received any regulatory designations?
Yes. Sparsentan has been granted Orphan Drug Designation (ODD) and Fast Track status by the FDA for FSGS and IgAN, recognizing its potential as a breakthrough therapy for these rare and serious conditions.
Q What are the common side effects and how are they managed?
Sparsentan is generally well-tolerated. The most commonly reported adverse effects include peripheral edema, hypotension, and hyperkalemia. These are typically manageable through dose adjustment, and regular monitoring of renal function and electrolyte levels is recommended throughout therapy.
Q Are there potential future applications for Sparsentan beyond FSGS and IgAN?
Yes. Sparsentan is currently being investigated for other proteinuric kidney diseases, including diabetic nephropathy and membranous nephropathy. Its dual-action mechanism makes it a promising candidate for a broader range of glomerular conditions.

Leave Your Message